Cancer researchers are one step closer to developing an effective vaccine to treat people with clear cell renal cell ...

In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated ...

Vaccines generated using the cells left over after tumour removal surgery could help to keep patients from redeveloping ...

Thomas Hutson, DO, PharmD, discusses key takeaways from the phase 3 CLEAR trial evaluating lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.

A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to ...

Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a ...

In a clinical trial, patients treated with a kidney cancer vaccine remained cancer-free after a median of nearly three years.

After their advanced kidney tumors were surgically removed, nine patients were protected from the cancer returning thanks to ...

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...

All patients involved in the phase 1 trial of a personalized cancer vaccine for high-risk stage III/IV kidney cancer showed a ...

Researchers evaluated a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear ...